These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 38907273)

  • 21. Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases.
    Zhang M; Rodrigues AJ; Pollom EL; Gibbs IC; Soltys SG; Hancock SL; Neal JW; Padda SK; Ramchandran KJ; Wakelee HA; Chang SD; Lim M; Hayden Gephart M; Li G
    J Neurooncol; 2021 Mar; 152(1):125-134. PubMed ID: 33415659
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Which Is More Suitable for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer, PD-L1 Inhibitors Versus PD-1 Inhibitors? A Systematic Review and Network Meta-Analysis.
    Liu W; Yu L; Feng Y; Huang S; Hua Y; Peng M; Ruan S; Zhang K
    Clin Respir J; 2024 Jul; 18(7):e13804. PubMed ID: 39073269
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PIV and PILE Score at Baseline Predict Clinical Outcome of Anti-PD-1/PD-L1 Inhibitor Combined With Chemotherapy in Extensive-Stage Small Cell Lung Cancer Patients.
    Zeng R; Liu F; Fang C; Yang J; Luo L; Yue P; Gao B; Dong Y; Xiang Y
    Front Immunol; 2021; 12():724443. PubMed ID: 34777341
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
    Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
    BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer.
    Shao J; Wang C; Ren P; Jiang Y; Tian P; Li W
    Biosci Rep; 2020 May; 40(5):. PubMed ID: 32315071
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biomarker role of thyroid irAE and PD-L1 positivity in predicting PD-1 blockade efficacy in patients with non-small cell lung cancer.
    Kim HI; Kim WG; Kim M; Ko NG; Jin M; Jung HA; Sun JM; Ahn JS; Ahn MJ; Choi YL; Jeon MJ; Kim TY; Kim WB; Kim SW; Lee DH; Jang SJ; Kim SW; Chung JH; Kim TH; Lee SH
    Cancer Immunol Immunother; 2024 Oct; 73(12):260. PubMed ID: 39382668
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
    Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
    Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
    Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
    Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.
    Grangeon M; Tomasini P; Chaleat S; Jeanson A; Souquet-Bressand M; Khobta N; Bermudez J; Trigui Y; Greillier L; Blanchon M; Boucekine M; Mascaux C; Barlesi F
    Clin Lung Cancer; 2019 May; 20(3):201-207. PubMed ID: 30442524
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation.
    Russano M; Cortellini A; Giusti R; Russo A; Zoratto F; Rastelli F; Gelibter A; Chiari R; Nigro O; De Tursi M; Bracarda S; Gori S; Grossi F; Bersanelli M; Calvetti L; Di Noia V; Scartozzi M; Di Maio M; Bossi P; Falcone A; Citarella F; Pantano F; Ficorella C; Filetti M; Adamo V; Veltri E; Pergolesi F; Occhipinti MA; Nicolardi L; Tuzi A; Di Marino P; Macrini S; Inno A; Ghidini M; Buti S; Aprile G; Lai E; Audisio M; Intagliata S; Marconcini R; Brocco D; Porzio G; Piras M; Rijavec E; Simionato F; Natoli C; Tiseo M; Vincenzi B; Tonini G; Santini D
    Cancer Immunol Immunother; 2022 Apr; 71(4):865-874. PubMed ID: 34462870
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune-related [
    Santo G; Cucè M; Restuccia A; Del Giudice T; Tassone P; Cicone F; Tagliaferri P; Cascini GL
    Cancer Imaging; 2024 Sep; 24(1):125. PubMed ID: 39289716
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients.
    Cortellini A; Chiari R; Ricciuti B; Metro G; Perrone F; Tiseo M; Bersanelli M; Bordi P; Santini D; Giusti R; Grassadonia A; Di Marino P; Tinari N; De Tursi M; Zoratto F; Veltri E; Malorgio F; Garufi C; Russano M; Anesi C; Zeppola T; Filetti M; Marchetti P; Berardi R; Rinaldi S; Tudini M; Silva RR; Pireddu A; Atzori F; Iacono D; Migliorino MR; Porzio G; Cannita K; Ficorella C; Buti S
    Clin Lung Cancer; 2019 Jul; 20(4):237-247.e1. PubMed ID: 30885550
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small cell lung cancer: A systematic review and meta-analysis.
    Zhang S; Li S; Cheng Y
    Thorac Cancer; 2020 Dec; 11(12):3536-3546. PubMed ID: 33058504
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune-related adverse events of a PD-L1 inhibitor plus chemotherapy versus a PD-L1 inhibitor alone in first-line treatment for advanced non-small cell lung cancer: A meta-analysis of randomized control trials.
    Wang M; Liang H; Wang W; Zhao S; Cai X; Zhao Y; Li C; Cheng B; Xiong S; Li J; He J; Liang W
    Cancer; 2021 Mar; 127(5):777-786. PubMed ID: 33119182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of PD-1/PD-L1 inhibitors in elderly patients with advanced non-small cell lung cancer.
    Li L; Xu C; Wang W; Zhang Q
    Clin Respir J; 2024 May; 18(5):e13763. PubMed ID: 38717297
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
    Ricciuti B; Genova C; De Giglio A; Bassanelli M; Dal Bello MG; Metro G; Brambilla M; Baglivo S; Grossi F; Chiari R
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):479-485. PubMed ID: 30506406
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors.
    Xu S; Lai R; Zhao Q; Zhao P; Zhao R; Guo Z
    Front Immunol; 2021; 12():794099. PubMed ID: 34950153
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of the prognostic nutrition index as a predictive biomarker in small-cell lung cancer patients undergoing immune checkpoint inhibitor treatment in the Chinese alpine region.
    Wu Y; Yang J; Qiao X; Li Y; Zhao R; Lin T; Li X; Wang M
    Front Oncol; 2023; 13():1041140. PubMed ID: 37007079
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients.
    Kotwal A; Kottschade L; Ryder M
    Thyroid; 2020 Feb; 30(2):177-184. PubMed ID: 31813343
    [No Abstract]   [Full Text] [Related]  

  • 40. Post-treatment neutrophil-to-lymphocyte ratio (NLR) predicts response to anti-PD-1/PD-L1 antibody in SCLC patients at early phase.
    Xiong Q; Huang Z; Xin L; Qin B; Zhao X; Zhang J; Shi W; Yang B; Zhang G; Hu Y
    Cancer Immunol Immunother; 2021 Mar; 70(3):713-720. PubMed ID: 32910245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.